18% of the population. One Vision. Continuous adversarial verification.
Saudi Arabia carries 18% diabetes prevalence — one of the highest in the world. The Ministry of Health has named lower-extremity amputation reduction a stated Vision 2030 priority. AimwellBio runs adversarial intelligence scoped to SFDA approvals, MOHAP procurement cycles, MOH formulary decisions, and the GCC + MENA manufacturing layer that supplies them. Wound care + diabetes are tracked together because the diabetic foot ulcer is where the two indications collide — and where Vision 2030 outcomes are won or lost.
18% of the KSA population. Among the highest globally. The number is the policy.
Diabetic foot ulcer is the operational endpoint where diabetes becomes wound care. MOH outcome targets fall here. Tracking the indication intersection is non-optional.
KSA + GCC manufacturing localization is no longer aspirational. Six anchored manufacturers under continuous monitoring.
Saudi Pharmaceutical Industries & Medical Appliances Corp.; primary Saudi-domiciled manufacturer with active diabetes-formulary portfolio aligned to MOH procurement.
Saudi diabetes-care manufacturer headquartered in Tabuk; SFDA-aligned production for Vision 2030 sovereign-supply mandates.
Jeddah-based Saudi pharmaceutical group; diabetes and cardiometabolic portfolio expansion across MENA; Vision 2030-aligned localization.
Gulf Pharmaceutical Industries (UAE); first GCC manufacturer of recombinant insulin; sovereign-supply anchor for the Gulf diabetes population.
Jordan-headquartered; Levant + MENA + U.S. injectables footprint; broad diabetes-injectable manufacturing relevant to GCC sovereign procurement.
Cairo-based generic and branded manufacturer; substantial MENA diabetes-formulary footprint; cross-border supply to GCC sovereign markets.
AimwellBio cross-tags every diabetic foot ulcer signal as both wound-care AND diabetes. Currently tracking — cross-tagged signals.
The DFU is the clinical surface where MOH amputation-reduction targets are measured. Single-indication coverage misses it. Combined-vector coverage anchors it.
This page is generated from a live ingest pipeline (tools/scout-ingest) covering FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, with CMS LCD, USPTO Patent Center, and manufacturer pipeline pages calibrating. Updated —.
Confidence framework: source-backed > pattern-inferred > model-hypothesis > speculative. Sovereign vectors apply additional MOH / SFDA / MOHAP context layers as those data feeds come online.